Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Archit Organosys
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 46.55 | 31.00 | 26.39 | 24.81 | 30.99 | 27.00 | 29.54 | 25.87 | 43.18 | 33.20 | 32.86 | 38.40 | 36.50 |
| Expenses + | 43.63 | 27.76 | 24.28 | 23.71 | 30.70 | 23.95 | 26.69 | 23.21 | 38.76 | 29.06 | 30.16 | 33.72 | 31.61 |
| Operating Profit | 2.92 | 3.24 | 2.11 | 1.10 | 0.29 | 3.05 | 2.85 | 2.66 | 4.42 | 4.14 | 2.70 | 4.68 | 4.89 |
| OPM % | 6.27% | 10.45% | 8.00% | 4.43% | 0.94% | 11.30% | 9.65% | 10.28% | 10.24% | 12.47% | 8.22% | 12.19% | 13.40% |
| Other Income + | 1.35 | 0.71 | 0.54 | 0.52 | 4.11 | 0.47 | 0.63 | 0.93 | 1.06 | 1.00 | 1.46 | 0.90 | -0.47 |
| Interest | 0.50 | 0.52 | 0.65 | 0.77 | 0.64 | 0.62 | 0.78 | 0.47 | 0.71 | 0.60 | 0.67 | 0.56 | 0.46 |
| Depreciation | 1.17 | 1.19 | 1.49 | 1.49 | 1.48 | 1.49 | 1.50 | 1.49 | 1.46 | 1.49 | 1.52 | 1.52 | 1.49 |
| Profit before tax | 2.60 | 2.24 | 0.51 | -0.64 | 2.28 | 1.41 | 1.20 | 1.63 | 3.31 | 3.05 | 1.97 | 3.50 | 2.47 |
| Tax % | 22.69% | 26.79% | 27.45% | -29.69% | 21.49% | 29.08% | 15.00% | 37.42% | 38.67% | 33.11% | 21.83% | 30.86% | 18.22% |
| Net Profit + | 2.01 | 1.64 | 0.37 | -0.46 | 1.79 | 1.01 | 1.02 | 1.01 | 2.02 | 2.04 | 1.54 | 2.43 | 2.02 |
| EPS in Rs | 0.98 | 0.80 | 0.18 | -0.22 | 0.87 | 0.49 | 0.50 | 0.49 | 0.98 | 0.99 | 0.75 | 1.18 | 0.98 |
Financials of Archit Organosys
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 56 | 51 | 48 | 82 | 84 | 77 | 95 | 138 | 128 | 113 | 126 | 141 |
| Expenses + | 53 | 48 | 44 | 78 | 87 | 73 | 83 | 121 | 108 | 106 | 113 | 125 |
| Operating Profit | 2 | 3 | 4 | 4 | -3 | 4 | 11 | 17 | 20 | 7 | 13 | 16 |
| OPM % | 4% | 6% | 8% | 5% | -4% | 5% | 12% | 12% | 15% | 6% | 10% | 12% |
| Other Income + | 1 | 1 | 0 | 3 | 3 | 2 | 0 | 1 | 3 | 6 | 3 | 3 |
| Interest | 1 | 1 | 1 | 4 | 4 | 3 | 3 | 2 | 2 | 3 | 3 | 2 |
| Depreciation | 0 | 0 | 1 | 3 | 3 | 3 | 4 | 5 | 5 | 6 | 6 | 6 |
| Profit before tax | 1 | 2 | 3 | 0 | -6 | -1 | 5 | 11 | 15 | 4 | 8 | 11 |
| Tax % | 43% | 37% | 42% | -32% | -25% | 1% | -7% | 28% | 26% | 24% | 33% | 27% |
| Net Profit + | 1 | 1 | 2 | 1 | -5 | -1 | 5 | 8 | 11 | 3 | 5 | 8 |
| EPS in Rs | 0.87 | 0.97 | 1.14 | 0.34 | -3.14 | -0.53 | 3.34 | 4.01 | 5.57 | 1.63 | 2.46 | 3.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 15% | 19% | 9% | 0% | 0% | 26% |
Financials of Archit Organosys
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 5 | 10 | 15 | 15 | 15 | 15 | 21 | 21 | 21 | 21 | 21 |
| Reserves | 2 | 8 | 17 | 25 | 20 | 19 | 26 | 31 | 41 | 44 | 49 | 56 |
| Borrowings + | 9 | 11 | 31 | 36 | 37 | 33 | 30 | 34 | 31 | 26 | 28 | 25 |
| Other Liabilities + | 10 | 8 | 12 | 26 | 12 | 16 | 17 | 18 | 27 | 18 | 26 | 25 |
| Total Liabilities | 24 | 32 | 70 | 101 | 84 | 83 | 87 | 104 | 120 | 108 | 123 | 127 |
| Fixed Assets + | 6 | 6 | 47 | 47 | 47 | 50 | 48 | 45 | 50 | 60 | 54 | 50 |
| CWIP | 0 | 8 | 1 | 8 | 5 | 1 | 3 | 13 | 14 | 1 | 1 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 6 | 6 | 7 |
| Other Assets + | 18 | 18 | 22 | 46 | 32 | 32 | 37 | 44 | 52 | 42 | 62 | 70 |
| Total Assets | 24 | 32 | 70 | 101 | 84 | 83 | 87 | 104 | 120 | 108 | 123 | 127 |
Financials of Archit Organosys
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 2 | 1 | 2 | -4 | 3 | 8 | 11 | 11 | 18 | 10 | 19 | 3 |
| Cash from Investing Activity + | -2 | -8 | -35 | -9 | 1 | -1 | -3 | -12 | -12 | -2 | -21 | 4 |
| Cash from Financing Activity + | 1 | 7 | 32 | 13 | 0 | -9 | -7 | 2 | -7 | -9 | -1 | -6 |
| Net Cash Flow | 0 | -0 | -0 | 0 | 4 | -2 | 1 | 2 | -0 | -1 | -4 | 1 |
| Free Cash Flow | -0 | -7 | -32 | -13 | 3 | 6 | 8 | -0 | 9 | 15 | 18 | 1 |
| CFO/OP | 93% | 57% | 75% | -90% | -97% | 221% | 99% | 71% | 108% | 164% | 150% | 30% |
Financials of Archit Organosys
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 76 | 79 | 86 | 140 | 62 | 94 | 97 | 72 | 107 | 72 | 67 | 64 |
| Inventory Days | 28 | 28 | 27 | 41 | 30 | 22 | 21 | 22 | 16 | 16 | 18 | 11 |
| Days Payable | 72 | 63 | 80 | 126 | 55 | 88 | 87 | 51 | 110 | 62 | 94 | 65 |
| Cash Conversion Cycle | 33 | 44 | 33 | 56 | 38 | 28 | 30 | 44 | 13 | 26 | -8 | 10 |
| Working Capital Days | -1 | 3 | 19 | 12 | -23 | -39 | -15 | -0 | 10 | 10 | 45 | 40 |
| ROCE % | 20% | 17% | 9% | 6% | -4% | 3% | 12% | 18% | 17% | 4% | 11% | 13% |
EBITDA margin improvement potential in explosive business to reach mid-teens (18-19% global benchmarks), with combined Solar-BME margins currently at 13-14%…
The net debt has already been reduced significantly from Rs.922 Crores at acquisition to Rs.531 Crores. Key concall takeaways from Sudarshan Chemical…
250-260 crores in FY27 with about 20% EBITDA margin, growing at 11-12% annually in absolute terms. Key concall takeaways from Indo Borax & Chemicals Ltd's Q1…
Chemicals business is guided for 15-20% growth in FY27, with a strong Q1 performance positioning the company to possibly hit the higher end of this range (Page…